Alzheimer's Disease Research

Alzheimer's disease (AD), the most common type of dementia, is an irreversible and progressive neurodegenerative disorder causing cognitive and functional impairment. It is characterized by formation of protein aggregates and progressive loss of neurons in the central nervous system (CNS). The symptoms of AD include short-term memory loss, confusion, irritability, aggression and mood swings, progressing to long-term memory deficit, withdrawal from social interactions and subsequently a loss in higher central functioning.

Alzheimer's Disease Research Products Targets

Products for Alzheimer's Disease Research - Page 36

Cat.No. Product Name Information/Activity
BCC7758 5,7-Dichlorokynurenic acid sodium salt 1184986-70-6
BCC6619 (±)-1-(1,2-Diphenylethyl)piperidine maleate 207461-99-2
BCC6205 DQP 1105 380560-89-4
BCC7280 Eliprodil Eliprodil(SL-820715) is a non-competitive NR2B-NMDA receptor antagonist(IC50=1 uM), less potent for NR2A- and NR2C-containing receptors(IC50> 100 uM).
BCC4904 Felbamate Felbamate (W-554) is a potent nonsedative anticonvulsant whose clinical effect may be related to the inhibition of N-methyl-D-aspartate (NMDA).
BCC4456 Flupirtine maleate Flupirtine Maleate(D 9998) is a selective neuronal potassium channel opener that also has NMDA receptor antagonist properties.
BCC7340 Gavestinel 153436-38-5
BCC6589 (S)-(-)-HA-966 111821-58-0
BCC5946 HU 211 Dexanabinol (HU-211) is an artificially synthesized cannabinoid derivative and lacks cannabimimetic effects. Dexanabinol exhibits not only the antioxidant and neuroprotective activities in brain but also anti-inflammatory activity by inhibiting NF-κB and decreasing cytokines such as TNFα and interleukin-6, which could ensure the integrity of BBB and reduce cell apoptosis and death. Dexanabinol is widely used in head injury or stroke treatment and has been shown to be safe in animals and humans.
BCC6594 N-(4-Hydroxyphenylacetyl)spermine 130210-32-1